Endologix Stung By Double-Whammy Suspensions
The specialist in stent grafts for abdominal aortic aneurysms, Endologix, has suspended shipments of its AFX AAA repair system after discovering that a manufacturing issue was causing damage to some devices. This is the second knock-back the company's biggest seller has had in as many weeks, following a CE-mark suspension earlier this month.
You may also be interested in...
Endovascular aortic repair specialist Endologix has promoted its COO John Onopchenko to the role of chief executive. He succeeds John McDermott, who stepped down as CEO in February following a couple of challenging years for the company.
The Dec. 29 announcement relating to non-EU shipments of AFX and some AFX2 AAA repair devices came two days after the company said it suspended shipments of its flagship system because a manufacturing issue was causing damage to some devices. The release of the hold allowed the company to end a difficult month on a positive note. Endologix announced the suspension of the CE mark for AFX and AFX2 in Europe earlier in December.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.